Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Kasteler, R; Kam, LMH; Weiss, A; Waespe, N; Sommer, G; Singer, F; von, der, Weid, NX; Ansari, M; Kuehni, CE, , Swiss, Pediatric, Oncology, Group, (SPOG).
Monitoring pulmonary health in Swiss childhood cancer survivors.
Pediatr Blood Cancer. 2018; 65(10):e27255
Doi: 10.1002/pbc.27255
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Singer Florian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Childhood cancer survivors are at increased risk for pulmonary morbidity and mortality. International guidelines recommend pulmonary function tests (PFT) during follow-up care. This nationwide study assessed how many children received PFT within 5 years after pulmotoxic treatment in Switzerland, types of tests, and predictors for testing. METHODS: We included all children from the Swiss Childhood Cancer Registry who were diagnosed with cancer from 1990 to 2013 at age 0-16 years, survived for ≥2 years from diagnosis, and had pulmotoxic chemotherapy with bleomycin, busulfan, nitrosoureas, and/or chest radiotherapy. We searched medical records in all Swiss pediatric oncology clinics for PFT (spirometry, plethysmography, diffusion capacity of carbon monoxide [DLCO]) and treatment details. RESULTS: We found medical records for 372 children, of whom 147 had pulmotoxic chemotherapy and 323 chest radiotherapy. Only 185 had plethysmography and/or spirometry (50%), 122 had DLCO (33%). Testing varied by cancer center from 3% to 79% (P = 0.001). Central nervous system tumor survivors and those not treated according to study protocols had less plethysmography and/or spirometry (odds ratio (OR) 0.3 and 0.3), lymphoma survivors and those who were symptomatic had more PFT (plethysmography and/or spirometry: OR 5.9 and 8.7; DLCO: OR 3.4 and 2.3). Cumulative incidence (CuI) of PFT was 52% in the first 5 years after pulmotoxic treatment; most of the tests were done in the first 2 years after treatment (CuI 44%). CONCLUSION: Only half of the survivors exposed to pulmotoxic treatment have been followed up with PFT in Switzerland. We need to optimize, update, and implement monitoring guidelines.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent - administration & dosage
- Antineoplastic Agents - adverse effects
- Cancer Survivors - administration & dosage
- Child - administration & dosage
- Child, Preschool - administration & dosage
- Female - administration & dosage
- Humans - administration & dosage
- Incidence - administration & dosage
- Infant - administration & dosage
- Infant, Newborn - administration & dosage
- Lung Diseases - diagnosis, epidemiology, etiology
- Male - administration & dosage
- Neoplasms - therapy
- Radiation Injuries - diagnosis, epidemiology
- Registries - administration & dosage
- Respiratory Function Tests - administration & dosage
- Retrospective Studies - administration & dosage
- Switzerland - epidemiology
- Find related publications in this database (Keywords)
- childhood cancer survivors
- Europe
- lung function measurements
- pulmotoxic
- Swiss Childhood Cancer Registry